<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="other"><?properties open_access?><!-- Original-type: cl--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">12942107</article-id><article-id pub-id-type="pmc">2394466</article-id><article-id pub-id-type="pii">6601217</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6601217</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical</subject></subj-group></article-categories><title-group><article-title>Phase I&#x0002f;II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kiura</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Ueoka</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Segawa</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Tabata</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kamei</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Takigawa</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hiraki</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Watanabe</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bessho</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Eguchi</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Okimoto</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Harita</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Takemoto</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hiraki</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Harada</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tanimoto</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><sup>1</sup>Second Department of Internal Medicine, Okayama University Medical School, Okayama, Japan</aff><aff id="aff2"><label>2</label><sup>2</sup>Department of Radiology, Okayama University Medical School, Okayama, Japan</aff><aff id="aff3"><label>3</label><sup>3</sup>Department of Internal Medicine, Okayama Red Cross Hospital, Okayama, Japan</aff><aff id="aff4"><label>4</label><sup>4</sup>Department of Internal Medicine, Sumitomo Besshi General Hospital, Niihama, Japan</aff><aff id="aff5"><label>5</label><sup>5</sup>Department of Medicine, Kawasaki Hospital, Kawasaki Medical School, Okayama, Japan</aff><aff id="aff6"><label>6</label><sup>6</sup>Department of Internal Medicine, Chugoku Chuoh Hospital of the Mutual Aid Association of Public School Teachers, Fukuyama, Japan</aff><aff id="aff7"><label>7</label><sup>7</sup>Department of Internal Medicine, National Shikoku Cancer Center Hospital, Matsuyama, Japan</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:kkiura@md.okayama-u.ac.jp">kkiura@md.okayama-u.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>08</month><year>2003</year></pub-date><pub-date pub-type="ppub"><day>01</day><month>09</month><year>2003</year></pub-date><volume>89</volume><issue>5</issue><fpage>795</fpage><lpage>802</lpage><history><date date-type="received"><day>18</day><month>11</month><year>2002</year></date><date date-type="rev-recd"><day>30</day><month>05</month><year>2005</year></date><date date-type="accepted"><day>29</day><month>06</month><year>2003</year></date></history><copyright-statement>Copyright 2003, Cancer Research UK</copyright-statement><copyright-year>2003</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><kwd-group><kwd>combination chemotherapy</kwd><kwd>concurrent chemoradiation</kwd><kwd>lung cancer</kwd><kwd>cisplatin</kwd><kwd>docetaxel</kwd></kwd-group></article-meta></front><body><p>Stage III non-small-cell lung cancer (NSCLC) represents a large patient population, accounting for approximately 30&#x00025; of all NSCLC patients (<xref ref-type="other" rid="bib43">van Meerbeeck, 2001</xref>). This stage has been intensively investigated for the last 10 years. Several studies and meta-analyses have documented an improvement in patients with stage III disease treated with chemotherapy followed by thoracic radiation therapy, compared with radiation therapy alone (<xref ref-type="other" rid="bib21">Marino <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib12">Dillman <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib33">Sause <italic>et al</italic>, 2000</xref>). Full-dose cisplatin-based chemotherapy with concurrent thoracic radiation therapy produced encouraging results with relatively severe toxicities (<xref ref-type="other" rid="bib20">Lee <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib29">Reboul <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib36">Segawa <italic>et al</italic>, 2000</xref>). Furthermore, results of a randomised trial demonstrated that concurrent administration of cisplatin-based chemotherapy and radiation significantly improved response rate and median survival compared with sequential administration (<xref ref-type="other" rid="bib14">Furuse <italic>et al</italic>, 1999</xref>); this finding is being confirmed by the Radiation Therapy Oncology Group (RTOG) 9410 trial (<xref ref-type="other" rid="bib9">Curran <italic>et al</italic>, 2000</xref>). Recently, several new agents with potent activity in the treatment of NSCLC have become available. The use of combination chemotherapy including these new drugs has improved the survival of patients with advanced NSCLC (<xref ref-type="other" rid="bib15">Giaccone <italic>et al</italic>, 1998</xref>). The feasibilities obtained with concomitant chemoradiotherapy regimens that include new agents are being reported (<xref ref-type="other" rid="bib17">Greco <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib25">Mauer <italic>et al</italic>, 1998</xref>).</p><p>Cisplatin causes a synergistic effect when given simultaneously with radiation both <italic>ex vivo</italic> and <italic>in vivo</italic> (<xref ref-type="other" rid="bib2">Alvarez <italic>et al</italic>, 1978</xref>; <xref ref-type="other" rid="bib11">Dewit, 1987</xref>). Docetaxel also shows a potential radiosensitising effect both <italic>ex vivo</italic> and <italic>in vivo</italic> (<xref ref-type="other" rid="bib22">Mason <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib8">Creane <italic>et al</italic>, 1999</xref>). The combination of docetaxel and cisplatin shows additive effects in lung cancer cell lines (<xref ref-type="other" rid="bib3">Aoe <italic>et al</italic>, 1999</xref>), and the antitumour spectrums of cisplatin and docetaxel on various lung cancer cell lines are completely different (<xref ref-type="other" rid="bib24">Matsushita <italic>et al</italic>, 1999</xref>). In clinical trials, the docetaxel&#x0002f;cisplatin combination is one of the most active treatments of advanced NSCLC (<xref ref-type="other" rid="bib31">Rodriguez <italic>et al</italic>, 2001</xref>). Moreover, patients with relapsed NSCLC treated with single-agent docetaxel had prolonged survival, even after receiving cisplatin-based chemotherapy previously (<xref ref-type="other" rid="bib37">Shepherd <italic>et al</italic>, 2000</xref>). Studies demonstrated that a weekly administration schedule of docetaxel resulted in markedly reduced myelosuppression compared with every 3-week administration (<xref ref-type="other" rid="bib39">Tomiak <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib18">Hainsworth <italic>et al</italic>, 1998</xref>). Since the weekly schedule may improve therapeutic outcome by increasing the dose intensity of docetaxel while reducing bone marrow toxicity from concurrent radiation therapy, the divided schedule of docetaxel on days on 1, 8, 29, and 36 was also considered to have the same advantage.</p><p>Based on these concepts, this phase I&#x0002f;II study was conducted to evaluate the safety, toxicity, antitumour activity, and survival effects of chemotherapy consisting of docetaxel plus cisplatin given on days 1, 8, 29, and 36 and concurrent thoracic radiation therapy in patients with locally advanced NSCLC. We planned to administer both cisplatin and docetaxel in as high doses and as early as possible to pursue both local control and eradication of distant micrometastasis.</p><sec sec-type="methods"><title>PATIENTS AND METHODS</title><sec><title>Eligibility criteria</title><p>Patients with histologically or cytologically confirmed NSCLC, unresectable stage IIIA or IIIB disease, were eligible for the study; however, those with T3N1 disease, malignant pleural effusion, pericardial effusion, or pleural dissemination were excluded. Other entry criteria included previously untreated disease, measurable lesion, Eastern Cooperative Oncology Group (ECOG) performance status (PS) (<xref ref-type="other" rid="bib28">Oken <italic>et al</italic>, 1982</xref>) &#x02a7d;1, age &#x02a7d;75 years, and no history of malignancy within 5 years of study. Before enrolment, each patient had a complete medical history and physical, laboratory, and staging assessments. The laboratory examinations consisted of complete blood cell count (CBC), serum chemistry and tumour marker analyses, 24-h creatinine clearance evaluation, arterial blood gas analysis, urinalysis, electrocardiogram, and pulmonary function tests. Staging work-up included chest plain radiographs, computed tomography (CT) scan of the chest and abdomen (ultrasonography of the abdomen could be substituted), magnetic resonance imaging of the brain, radionuclide bone scan, and bronchofiberscopy. Mediastinoscopy was not included in the staging work-up. A mediastinal lymph node &#x02a7e;10&#x02009;mm along the short axis by CT scan was defined as a metastatic lymph node (N2-3). Patients were required to have a white blood cell (WBC) count &#x02a7e;4000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup>, platelet (PLT) count &#x02a7e;100,000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup>, haemoglobin level &#x02a7e;9&#x02009;g&#x02009;dl<sup>&#x02212;1</sup>, serum bilirubin level&#x02a7d;1.5&#x02009;mg&#x02009;dl<sup>&#x02212;1</sup>, serum aspartate aminotransferase and alanine aminotransferase levels &#x02a7d;2.5 times the upper normal limit, serum creatinine level &#x02a7d;1.5&#x02009;mg&#x02009;dl<sup>&#x02212;1</sup>, 24-h creatinine clearance level &#x02a7e;60&#x02009;ml&#x02009;min<sup>&#x02212;1</sup>, and arterial oxygen pressure (PaO<sub>2</sub>)&#x02a7e;60&#x02009;mmHg. Patients were excluded if they had markedly diminished vital capacity and&#x0002f;or forced expiratory volume in 1&#x02009;s, any serious underlying diseases or complications, or were women who were pregnant, breast feeding, or of child-bearing age. Written informed consent was obtained from all patients.</p></sec><sec><title>Response and toxicity evaluations</title><p>For the evaluation of response and toxicity, all patients underwent a CBC and serum chemistry analysis two to three times a week, urinalysis, and chest plain radiograph at least weekly during the treatment and at least monthly thereafter; a CT scan of the chest was taken on days 22 and 50 and every 3 months for 2 years; examinations performed at staging work-up were repeated after the completion of treatment. Response was assessed by extramural reviewers using ECOG criteria (<xref ref-type="other" rid="bib28">Oken <italic>et al</italic>, 1982</xref>). The response rate was determined on an &#x02018;intention-to-treat&#x02019; basis. Toxicity was assessed and graded using ECOG common toxicity criteria (<xref ref-type="other" rid="bib28">Oken <italic>et al</italic>, 1982</xref>). The grading of acute oesophageal and pulmonary toxicities due to radiation was in accordance with RTOG&#x0002f;European Organization for Research and Treatment of Cancer (EORTC) radiation acute toxicity criteria (<xref ref-type="other" rid="bib7">Cox <italic>et al</italic>, 1995</xref>). Dose limiting toxicity (DLT) was defined as grade &#x02a7e;3 haematologic toxicity lasting 3 days or longer, grade &#x02a7e;3 radiation oesophagitis, or any nonhaematologic grade 3 or higher toxicities except hair loss and nausea&#x0002f;vomiting.</p></sec><sec><title>Phase I study</title><p>The primary end point of the phase I portion of the study was to determine the maximum-tolerated doses (MTDs) and the recommended doses (RDs) of docetaxel and cisplatin for the phase II study when combined with 60&#x02009;Gy of concurrent thoracic radiation therapy for patients with locally advanced and surgically unresectable NSCLC.</p><sec><title>Dose escalation scheme</title><p>Dose levels of docetaxel and cisplatin are shown in <xref rid="tbl1" ref-type="table">Table 1</xref>
 <table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Dose-escalation scheme and principal toxicities in the phase I portion of the trial (<italic>n</italic>&#x0003d;33)</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Dose level</bold></th><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="." charoff="50"><bold>1</bold></th><th align="center" valign="top" char="." charoff="50"><bold>2</bold></th><th align="center" valign="top" char="." charoff="50"><bold>3</bold></th><th align="center" valign="top" char="." charoff="50"><bold>4</bold></th><th align="center" valign="top" char="." charoff="50"><bold>5</bold></th><th align="center" valign="top" char="." charoff="50"><bold>6</bold></th><th align="center" valign="top" char="." charoff="50"><bold>7</bold></th><th align="center" valign="top" char="." charoff="50"><bold>8</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Docetaxel (mg&#x02009;m<sup>&#x02212;2</sup>)</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" char="." charoff="50">20</td><td align="center" valign="top" char="." charoff="50">25</td><td align="center" valign="top" char="." charoff="50">30</td><td align="center" valign="top" char="." charoff="50">30</td><td align="left" valign="top" char="." charoff="50">30</td><td align="center" valign="top" char="." charoff="50">35</td><td align="left" valign="top" char="." charoff="50">40</td><td align="left" valign="top" char="." charoff="50">45</td></tr><tr><td align="left" valign="top" charoff="50">Cisplatin (mg&#x02009;m<sup>&#x02212;2</sup>)</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" char="." charoff="50">30</td><td align="center" valign="top" char="." charoff="50">30</td><td align="center" valign="top" char="." charoff="50">30</td><td align="center" valign="top" char="." charoff="50">35</td><td align="left" valign="top" char="." charoff="50">40</td><td align="center" valign="top" char="." charoff="50">40</td><td align="left" valign="top" char="." charoff="50">40</td><td align="left" valign="top" char="." charoff="50">40</td></tr><tr><td align="left" valign="top" charoff="50">No. of patients</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" char="." charoff="50">6</td><td align="center" valign="top" char="." charoff="50">3</td><td align="center" valign="top" char="." charoff="50">3</td><td align="center" valign="top" char="." charoff="50">3</td><td align="left" valign="top" char="." charoff="50">3</td><td align="center" valign="top" char="." charoff="50">3</td><td align="left" valign="top" char="." charoff="50">6</td><td align="left" valign="top" char="." charoff="50">6</td></tr><tr><td align="left" valign="top" charoff="50">No. of DLTs</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" char="." charoff="50">2</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td><td align="left" valign="top" char="." charoff="50">1</td><td align="center" valign="top" char="." charoff="50">0</td><td align="left" valign="top" char="." charoff="50">1</td><td align="left" valign="top" char="." charoff="50">4</td></tr><tr><td align="left" valign="top" charoff="50">Principal toxicity<sup>a</sup></td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Oesophagitis</td><td align="center" valign="top" charoff="50">G3</td><td align="left" valign="top" char="." charoff="50">2 (2)<sup>b</sup></td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" char="." charoff="50">1 (1)</td><td align="left" valign="top" char="." charoff="50">2 (2)</td></tr><tr><td align="left" valign="top" charoff="50">Liver</td><td align="center" valign="top" charoff="50">G3</td><td align="left" valign="top" char="(" charoff="50">1 (1)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Granulocytopenia</td><td align="center" valign="top" charoff="50">G3</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" char="(" charoff="50">1(1)</td><td align="center" valign="top" char="." charoff="50">1</td><td align="left" valign="top" char="(" charoff="50">4 (1)</td><td align="left" valign="top" char="(" charoff="50">2 (1)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">G4</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" char="(" charoff="50">2 (1)</td></tr><tr><td align="left" valign="top" charoff="50">Anaemia</td><td align="center" valign="top" charoff="50">G3</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">G4</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" char="." charoff="50">1</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Thrombocytopenia</td><td align="center" valign="top" charoff="50">G3</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" char="(" charoff="50">1 (1)</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label/><p>DLT&#x0003d;dose-limiting toxicity; G3&#x0003d;grade 3; G4&#x0003d;grade 4.</p></fn><fn id="tbfnote2"><label>a</label><p>Toxicity was assessed and graded using ECOG common toxicity criteria (Oken <italic>et al</italic>, 1982), and grading of acute oesophageal toxicity due to radiation was evaluated in accordance with RTOG&#x0002f; EORTC radiation acute toxicity criteria (Cox <italic>et al</italic>, 1995). </p></fn><fn id="tbfnote3"><label>b</label><p>Number of patients with grade 3 or 4 toxicity (numbers in parentheses indicate number of patients with the DLT).</p></fn></table-wrap-foot></table-wrap>. At least three patients were entered at each dose level. If a DLT occurred in two of three initial patients at a particular dose level, then three additional patients were treated at the same dose level to define the frequency of that toxicity. If three of three patients or at least four of six patients experienced the DLT, enrolment at this dose level was ceased, the dose level was determined as the MTD, and the preceding dose level was designated as the RD for the phase II study.</p></sec><sec><title>Treatment schedule and modifications</title><p>The treatment scheme is shown in <xref ref-type="fig" rid="fig1">Figure 1</xref><fig id="fig1"><label>Figure 1</label><caption><p>Treatment scheme of the phase I&#x0002f;II study of concurrent chemoradiotherapy with cisplatin and docetaxel in patients with advanced NSCLC. The arrow indicates shrinkage of the radiation field at a total dose of 40&#x02009;Gy.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="89-6601217f1"/></fig>. Docetaxel was administered intravenously over 1&#x02009;h followed by 1-h infusion of cisplatin before radiation therapy. Before and after cisplatin instillation, all patients received 2000&#x02013;2500&#x02009;ml of normal saline and 5&#x00025; glucose by infusion over 4&#x02009;h. Prophylactic antiemetic therapy using 5-hydroxytriptamine type III receptor blocker and dexamethasone was given to all patients. Patients experiencing grade 3 granulocytopenia with infection or grade 4 leukopenia or granulocytopenia subsequently received recombinant human granulocyte colony-stimulating factor (<italic>r</italic>hG-CSF: 2&#x02009;<italic>&#x003bc;</italic>g&#x02009;kg<sup>&#x02212;1</sup>) subcutaneously until leucocyte or neutrophil count recovered to &#x02a7e;5000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup> or &#x02a7e;2000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup>, respectively. Chemotherapy dose and schedule modifications for toxicity are shown in <xref rid="tbl2" ref-type="table">Table 2</xref>
 <table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Chemotherapy and radiotherapy dose and schedule modifications for toxicity<sup>a</sup></p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Toxicity</bold></th><th align="left" valign="top" charoff="50"><bold>Modification</bold></th></tr></thead><tbody valign="top"><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Chemotherapy</italic></td></tr><tr><td align="left" valign="top" charoff="50">Grade &#x02a7e;3 leukopenia, granulocytopenia, thrombocytopenia, on days 8 or 36</td><td align="left" valign="top" charoff="50">Docetaxel and cisplatin withheld</td></tr><tr><td align="left" valign="top" charoff="50">Grade &#x02a7e;3 leukopenia, granulocytopenia, thrombocytopenia, on day 29</td><td align="left" valign="top" charoff="50">Chemotherapy postponed until toxicity recovered to grade 2</td></tr><tr><td align="left" valign="top" charoff="50">Grade 2 leukopenia, granulocytopenia, thrombocytopenia on day 8, 29, or 36</td><td align="left" valign="top" charoff="50">Doses of both drugs reduced by 5&#x02009;mg&#x02009;m<sup>&#x02212;2</sup></td></tr><tr><td align="left" valign="top" charoff="50">24-h creatinine clearance 30&#x02013;60&#x02009;ml&#x02009;min<sup>&#x02212;1</sup>, or serum creatinine 1.5&#x02013;2.0&#x02009;mg&#x02009;dl<sup>&#x02212;1</sup></td><td align="left" valign="top" charoff="50">Cisplatin dose reduced to 30&#x02009;mg m<sup>&#x02212;2</sup></td></tr><tr><td align="left" valign="top" charoff="50">Creatinine clearance &#x0003c;30&#x02009;ml&#x02009;min<sup>&#x02212;1</sup>, or serum creatinine &#x0003e;2.0&#x02009;mg&#x02009;dl<sup>&#x02212;1</sup></td><td align="center" valign="top" charoff="50">Cisplatin withheld</td></tr><tr><td align="left" valign="top" charoff="50">Systemic oedema or fluid retention on day of chemotherapy administration</td><td align="left" valign="top" charoff="50">Docetaxel withheld</td></tr><tr><td align="left" valign="top" charoff="50">Nonhaematologic grade &#x02a7e;3 toxicity, except for hair loss or nausea&#x0002f;vomiting</td><td align="left" valign="top" charoff="50">Chemotherapy postponed until recovery</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Radiotherapy</italic></td></tr><tr><td align="left" valign="top" charoff="50">Grade &#x02a7e;3 radiation oesophagitis</td><td align="left" valign="top" charoff="50">Radiation withheld until recovery to grade &#x02a7d;2</td></tr><tr><td align="left" valign="top" charoff="50">Lung toxicity (10&#x02009;Torr&#x02193;PaO<sub>2</sub> from baseline)</td><td align="left" valign="top" charoff="50">Radiation withheld until PaO<sub>2</sub> decrease is &#x0003c;10&#x02009;Torr</td></tr><tr><td align="left" valign="top" charoff="50">Grade 3 granulocytopenia with infection or grade 4 leukopenia or granulocytopenia</td><td align="left" valign="top" charoff="50">Radiation discontinued and rhG-CSF (2&#x02009;<italic>&#x003bc;</italic>g&#x02009;kg<sup>&#x02212;1</sup>) administered until leucocyte count &#x02a7e;5000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup> or neutrophil count &#x02a7e;2000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup></td></tr><tr><td align="left" valign="top" charoff="50">Grade &#x02a7e;3 thrombocytopenia</td><td align="left" valign="top" charoff="50">Radiation withheld until platelet count &#x02a7e;25&#x02009;000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup></td></tr></tbody></table><table-wrap-foot><fn id="tbfnote4"><label>a</label><p>Chemotherapy and radiotherapy were discontinued if toxicities did not resolve within 12 weeks.</p></fn></table-wrap-foot></table-wrap>.</p><p>Radiation therapy was administered from day 1 of chemotherapy using a linear accelerator (6&#x02013;10&#x02009;MeV), in 2&#x02009;Gy single daily fractions for five consecutive days each week to a total dose of 60&#x02009;Gy.</p><p>Treatment planning was constructed for a curative radiation field using chest plain radiograph and contrast-enhanced CT scan before concomitant chemoradiotherapy. Principally, the initial radiation field was planned not to exceed 50&#x00025; of one lung. The initial dose (&#x0223c;40&#x02009;Gy) was administered to the original volume that consisted of primary tumour including the movement area by respiration and the ipsilateral hilum with 2&#x02009;cm margin, and all enlarged mediastinal lymph nodes (&#x02a7e;10&#x02009;mm along the short axis) detected by CT scan with 1&#x02009;cm margin, extending inferiorly to 3&#x02009;cm below the carina if subcarinal lymph nodes were involved. Other prophylactic radiation fields were not set up. The supraclavicular region was not routinely included if lymph nodes metastasis or primary tumour invasion was not detected. Subsequently, an additional 20&#x02009;Gy dose was administered to the boost volume, including the sites of primary tumour and hilar&#x0002f;mediatinal lymph nodes according to the tumour and lymph nodes shrinkage determined by contrast-enhanced CT scan on day 29 or later. The original volume was treated with an anterior&#x02013;posterior parallel-opposed pair of portals, and the boost volume was treated with the same pair or with a pair of oblique fields if the cumulative radiation dose to the spinal cord exceeded 40&#x02009;Gy. Radiation therapy dose and schedule modifications for toxicity are shown in <xref rid="tbl2" ref-type="table">Table 2</xref>.</p><p>The patients were carefully treated on an inpatient basis during the concomitant chemoradiotherapy.</p></sec></sec><sec><title>Phase II study</title><p>The primary end points of the phase II portion of the study were objective response rate and safety of this combined treatment modality at the RD level. The secondary end point was the 2-year survival rate. The same patient eligibility requirements, treatment schedules, dose and schedule modifications, and response and toxicity criteria as in the phase I portion of the study applied.</p></sec><sec><title>Statistical considerations</title><p>The sample size for the phase II study portion was calculated as 36 patients on the assumption that 70&#x00025; of patients would respond, with a 95&#x00025; confidence interval (CI) &#x000b1; 15&#x00025;. Assuming that 10&#x00025; of patients would not be evaluable for response, the accrual goal was 42 patients, including those who received chemoradiotherapy at the RD level in the phase I portion of the trial. The survival time was defined as the period from initiation of treatment to death or last follow-up evaluation, and event-free survival was defined as the period from initiation of treatment to PD or death due to causes other than NSCLC. The survival and event-free survival curves were calculated using the Kaplan and Meier method.</p></sec></sec><sec><title>RESULTS</title><sec><title>Patient characteristics</title><p>Between June 1997 and December 1999, 69 patients at Okayama University Hospital and 11 affiliated hospitals in Japan were enrolled in this phase I&#x0002f;II study. All patients had ECOG PS of 0&#x02013;1. In the phase I portion of the study, 33 patients were treated at one of eight dose levels (<xref rid="tbl1" ref-type="table">Table 1</xref>). The patients comprised 30 men and three women with a median age of 63 years (range, 29&#x02013;75 years). Fourteen (42&#x00025;) patients had squamous cell carcinoma, 13 (39&#x00025;) adenocarcinoma, three (9&#x00025;) large-cell carcinoma, and three (9&#x00025;) unclassified carcinoma. Nine (27&#x00025;) patients had stage IIIA and 24 (73&#x00025;) stage IIIB disease. Forty-two patients, including six who had received chemoradiotherapy at the RD level in phase I, were analysed in the phase II portion of the study (<xref rid="tbl3" ref-type="table">Table 3</xref>
 <table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Patient characteristics (phase II portion)</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="right" valign="top" char="." charoff="50"><bold>No. of patients</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">No. of patients evaluated&#x0002f;eligible</td><td align="right" valign="top" char="." charoff="50">42&#x0002f;42</td></tr><tr><td align="left" valign="top" charoff="50">Median age, year (range)</td><td align="right" valign="top" char="." charoff="50">67 (29&#x02013;75)</td></tr><tr><td align="left" valign="top" charoff="50">Sex: male&#x0002f;female</td><td align="right" valign="top" char="." charoff="50">36&#x0002f;6</td></tr><tr><td align="left" valign="top" charoff="50">ECOG PS: 0&#x0002f;1</td><td align="right" valign="top" char="." charoff="50">18&#x0002f;24</td></tr><tr><td align="left" valign="top" charoff="50">Weight loss</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;5&#x00025; or more</td><td align="right" valign="top" char="." charoff="50">5</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;Less than 5&#x00025;</td><td align="right" valign="top" char="." charoff="50">37</td></tr><tr><td align="left" valign="top" charoff="50">Histology</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;Adenocarcinoma</td><td align="right" valign="top" char="." charoff="50">12</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;Squamous cell carcinoma</td><td align="right" valign="top" char="." charoff="50">26</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;Unclassified</td><td align="right" valign="top" char="." charoff="50">4</td></tr><tr><td align="left" valign="top" charoff="50">Stage of disease: IIIA&#x0002f; IIIB</td><td align="right" valign="top" char="." charoff="50">8&#x0002f;34</td></tr><tr><td align="left" valign="top" charoff="50">TNM classification</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;T2N2M0</td><td align="right" valign="top" char="." charoff="50">5</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;T3N2M0</td><td align="right" valign="top" char="." charoff="50">3</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;T1N3M0</td><td align="right" valign="top" char="." charoff="50">2</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;T2N3M0</td><td align="right" valign="top" char="." charoff="50">5</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;T3N3M0</td><td align="right" valign="top" char="." charoff="50">4</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;T4N0M0</td><td align="right" valign="top" char="." charoff="50">3</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;T4N1M0</td><td align="right" valign="top" char="." charoff="50">3</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;T4N2M0</td><td align="right" valign="top" char="." charoff="50">15</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;T4N3M0</td><td align="right" valign="top" char="." charoff="50">2</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote5"><label/><p>ECOG&#x0003d;Eastern Corporative Oncology Group; PS&#x0003d;performance status.</p></fn></table-wrap-foot></table-wrap>). Overall, 36 men and six women with a median age of 67 years (range, 29&#x02013;75 years) were included. Twenty-six (62&#x00025;) patients had squamous cell carcinoma, 12 (29&#x00025;) adenocarcinoma, and four (10&#x00025;) unclassified carcinoma. Eight (19&#x00025;) patients had stage IIIA and 34 (81&#x00025;) had stage IIIB disease including three (7&#x00025;) with swelling of supraclavicular lymph nodes. Five (12&#x00025;) patients had 5&#x00025; or more weight loss within 6 months.</p></sec><sec><title>Phase I study</title><sec><title>Dose escalation and toxicity</title><p>The dose-escalation scheme and principal toxicities observed in the phase I portion of the study are summarised in <xref rid="tbl1" ref-type="table">Table 1</xref>. At the first dose level, two of the initial three patients developed grade 3 radiation oesophagitis that lasted for 19 and 8 days, respectively, and one of the two patients had grade 3 hepatic toxicity. None of three additional patients treated at the first dose level developed DLT. At dose level 5, one patient encountered grade 3 granulocytopenia on day 72, which continued to day 82. Although six patients were enrolled at dose level 7 for the safety, only one patient experienced DLT (grade 3 radiation oesophagitis and grade 3 granulocytopenia). Four of six patients at dose level 8 developed DLT (two with grade 3 radiation oesophagitis, one each with grade 4 granulocytopenia, and grade 3 granulocytopenia and thrombocytopenia). The MTD was determined to be dose level 8 (docetaxel 45&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, cisplatin 40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>), and dose level 7 (docetaxel 40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, cisplatin 40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) was adopted as the RD for the phase II study.</p></sec><sec><title>Response and survival</title><p>Among 33 entered patients, one (3&#x00025;) had complete response (CR), 22 (67&#x00025;) had partial response (PR), eight (24&#x00025;) had no change (NC), and one (3&#x00025;) had progressive disease (PD), for an overall response rate of 70&#x00025; (95&#x00025; CI, 55&#x02013;85&#x00025;). Overall and event-free survival curves for the 33 patients are shown in <xref ref-type="fig" rid="fig2">Figure 2A</xref><fig id="fig2"><label>Figure 2</label><caption><p>(<bold>A</bold>) Overall (solid line) and event-free (dotted line) survival for 33 patients with locally advanced NSCLC in the phase I portion of the study. (<bold>B</bold>) Overall (solid line) and event-free (dotted line) survival for 42 patients with locally advanced NSCLC in the phase II portion of the study. Censored cases are denoted by tics.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="89-6601217f2"/></fig>. At a median follow-up time of 39 months (range, 32&#x02013;51 months), 21 (64&#x00025;) patients had died and 12 (36&#x00025;) were still alive without disease. The causes of death were directly related to NSCLC in 20 patients and unrelated in one (suicide). Overall survival rates at 1, 2, and 3 years were 76, 49, and 36&#x00025;, respectively. The median survival time was 24 months. Event-free survival rates (mean) at 1, 2, and 3 years were 39, 36, and 36&#x00025;, respectively.</p></sec></sec><sec><title>Phase II study</title><sec><title>Response and survival</title><p>Responses in 42 patients entered in the phase II portion of the study were CR in one (2&#x00025;), PR in 32 (76&#x00025;), NC in eight (19&#x00025;), and PD in one (2&#x00025;), for an overall response rate of 79&#x00025; (95&#x00025; CI, 66&#x02013;91&#x00025;). <xref ref-type="fig" rid="fig2">Figure 2B</xref> shows overall survival for the 42 patients. At a median follow-up time of 26 months (range, 21&#x02013;36 months), 20 (48&#x00025;) patients had died and 22 (52&#x00025;) were still alive. The causes of death were directly related to NSCLC in 19 patients and pneumonia and radiation pneumonitis in one. Overall survival rates (mean) at 1 and 2 years were 76 and 54&#x00025;, respectively. The median survival time was 23.4&#x0002b; months. Event-free survival rates at 1 and 2 years were 55 and 38&#x00025;, respectively.</p></sec><sec><title>Toxicity</title><p>Toxicities observed in 42 patients during treatment and follow-up are listed in <xref rid="tbl4" ref-type="table">Tables 4</xref>
 <table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p content-type="table-title">Haematologic toxicities (phase II portion) (<italic>n</italic>&#x0003d;42)</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="5" align="center" valign="top" char="." charoff="50"><bold>No. of patients with grade</bold><hr/></th><th align="char" valign="top" char="." charoff="50">&#x000a0;</th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="." charoff="50"><bold>0</bold></th><th align="center" valign="top" char="." charoff="50"><bold>1</bold></th><th align="center" valign="top" char="." charoff="50"><bold>2</bold></th><th align="center" valign="top" char="." charoff="50"><bold>3</bold></th><th align="center" valign="top" char="." charoff="50"><bold>4</bold></th><th align="center" valign="top" char="." charoff="50"><bold>&#x00025; of toxicities grade &#x02a7e;3</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Leukopenia</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">2</td><td align="center" valign="top" char="." charoff="50">10</td><td align="center" valign="top" char="." charoff="50">24</td><td align="center" valign="top" char="." charoff="50">6</td><td align="center" valign="top" char="." charoff="50">71</td></tr><tr><td align="left" valign="top" charoff="50">Granulocytopenia</td><td align="center" valign="top" char="." charoff="50">2</td><td align="center" valign="top" char="." charoff="50">3</td><td align="center" valign="top" char="." charoff="50">12</td><td align="center" valign="top" char="." charoff="50">18</td><td align="center" valign="top" char="." charoff="50">7</td><td align="center" valign="top" char="." charoff="50">60</td></tr><tr><td align="left" valign="top" charoff="50">Anaemia</td><td align="center" valign="top" char="." charoff="50">1</td><td align="center" valign="top" char="." charoff="50">12</td><td align="center" valign="top" char="." charoff="50">19</td><td align="center" valign="top" char="." charoff="50">9</td><td align="center" valign="top" char="." charoff="50">1</td><td align="center" valign="top" char="." charoff="50">24</td></tr><tr><td align="left" valign="top" charoff="50">Thrombocytopenia</td><td align="center" valign="top" char="." charoff="50">35</td><td align="center" valign="top" char="." charoff="50">2</td><td align="center" valign="top" char="." charoff="50">2</td><td align="center" valign="top" char="." charoff="50">3</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">7</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote6"><label/><p>Haematologic toxicity was assessed and graded using ECOG common toxicity criteria (Oken <italic>et al</italic>, 1982).</p></fn></table-wrap-foot></table-wrap> and
 <xref rid="tbl5" ref-type="table">5</xref>
 <table-wrap id="tbl5" position="float"><label>Table 5</label><caption><p content-type="table-title">Nonhaematologic toxicities (phase II portion) (<italic>n</italic>&#x0003d;42)</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="6" align="center" valign="top" char="." charoff="50"><bold>No. of patients with grade</bold><hr/></th><th align="char" valign="top" char="." charoff="50">&#x000a0;</th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="." charoff="50"><bold>0</bold></th><th align="center" valign="top" char="." charoff="50"><bold>1</bold></th><th align="center" valign="top" char="." charoff="50"><bold>2</bold></th><th align="center" valign="top" char="." charoff="50"><bold>3</bold></th><th align="center" valign="top" char="." charoff="50"><bold>4</bold></th><th align="center" valign="top" char="." charoff="50"><bold>5</bold></th><th align="center" valign="top" char="." charoff="50"><bold>&#x00025; of toxicities grade &#x02a7e;3</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Nausea&#x0002f;vomiting</td><td align="center" valign="top" char="." charoff="50">9</td><td align="center" valign="top" char="." charoff="50">13</td><td align="center" valign="top" char="." charoff="50">15</td><td align="center" valign="top" char="." charoff="50">5</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">11.9</td></tr><tr><td align="left" valign="top" charoff="50">Diarrhoea</td><td align="center" valign="top" char="." charoff="50">28</td><td align="center" valign="top" char="." charoff="50">6</td><td align="center" valign="top" char="." charoff="50">5</td><td align="center" valign="top" char="." charoff="50">2</td><td align="center" valign="top" char="." charoff="50">1</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">7.1</td></tr><tr><td align="left" valign="top" charoff="50">Stomatitis</td><td align="center" valign="top" char="." charoff="50">37</td><td align="center" valign="top" char="." charoff="50">4</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">1</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">2.4</td></tr><tr><td align="left" valign="top" charoff="50">Neurologic</td><td align="center" valign="top" char="." charoff="50">40</td><td align="center" valign="top" char="." charoff="50">2</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Liver</td><td align="center" valign="top" char="." charoff="50">38</td><td align="center" valign="top" char="." charoff="50">1</td><td align="center" valign="top" char="." charoff="50">2</td><td align="center" valign="top" char="." charoff="50">1</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">2.4</td></tr><tr><td align="left" valign="top" charoff="50">Renal dysfunction</td><td align="center" valign="top" char="." charoff="50">41</td><td align="center" valign="top" char="." charoff="50">1</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Fever</td><td align="center" valign="top" char="." charoff="50">36</td><td align="center" valign="top" char="." charoff="50">1</td><td align="center" valign="top" char="." charoff="50">5</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Alopecia</td><td align="center" valign="top" char="." charoff="50">2</td><td align="center" valign="top" char="." charoff="50">28</td><td align="center" valign="top" char="." charoff="50">12</td><td align="center" valign="top" char="." charoff="50">&#x02014;</td><td align="center" valign="top" char="." charoff="50">&#x02014;</td><td align="center" valign="top" char="." charoff="50">&#x02014;</td><td align="center" valign="top" char="." charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">Oesophagitis</td><td align="center" valign="top" char="." charoff="50">13</td><td align="center" valign="top" char="." charoff="50">12</td><td align="center" valign="top" char="." charoff="50">9</td><td align="center" valign="top" char="." charoff="50">7</td><td align="center" valign="top" char="." charoff="50">1</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">19.0</td></tr><tr><td align="left" valign="top" charoff="50">Pneumonitis</td><td align="center" valign="top" char="." charoff="50">38</td><td align="center" valign="top" char="." charoff="50">3</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">1</td><td align="center" valign="top" char="." charoff="50">0</td><td align="center" valign="top" char="." charoff="50">1</td><td align="center" valign="top" char="." charoff="50">4.8</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote7"><label/><p>Nonhaematologic toxicity was assessed and graded using ECOG common toxicity criteria (Oken <italic>et al</italic>, 1982), and grading of acute oesophageal and pulmonary toxicities due to radiation was in accordance with RTOG&#x0002f;EORTC radiation acute toxicity criteria (Cox <italic>et al</italic>, 1995).</p></fn></table-wrap-foot></table-wrap>. The most common toxicity was leukopenia, which often occurred in conjunction with granulocytopenia. Grade &#x02a7e;3 leukopenia and granulocytopenia occurred in 30 (71&#x00025;) and 25 (60&#x00025;) patients, respectively. Recombinant human granulocyte colony stimulating factor was administered to 18 (43&#x00025;) patients for a median duration of 4 days (range, 1&#x02013;10 days). Grade &#x02a7e;3 thrombocytopenia and anaemia occurred in 10 (24&#x00025;) and three (7&#x00025;) patients, respectively. Grade &#x02a7e;3 radiation oesophagitis, radiation pneumonitis, hepatic dysfunction, and diarrhoea occurred in eight (19&#x00025;), two (5&#x00025;), one (2&#x00025;), and three (7&#x00025;) patients, respectively. The median WBC count nadir in eight patients with grade &#x02a7e;3 radiation oesophagitis was 1150&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup> (range, 500&#x02013;2300&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup>); grade &#x02a7e;3 leukopenia also occurred in 88&#x00025; of these eight patients. Overall, 32 (76&#x00025;) patients experienced any grade &#x02a7e;3 toxicity (haematologic only, 45&#x00025;; nonhaematologic only, 5&#x00025;; both, 26&#x00025;). At day 102 from the beginning of radiation therapy, one patient died of pneumonia and radiation pneumonitis. This patient was admitted to a local hospital because of acute respiratory failure, was treated as pneumonia, but died within a week. Autopsy was not carried out.</p></sec><sec><title>Initial relapse site</title><p>Nineteen patients were evaluable for sites of initial relapse in the phase II portion. The primary site was the first site of failure in nine patients (nine without and one with distant metastasis). Distant metastasis was the first site of the failure in 10 patients. Failure sites were as follows: lung (<italic>n</italic>&#x0003d;3), adrenal gland (<italic>n</italic>&#x0003d;2), bone (<italic>n</italic>&#x0003d;2), penis (<italic>n</italic>&#x0003d;1), brain (<italic>n</italic>&#x0003d;1), and skin (<italic>n</italic>&#x0003d;1).</p></sec><sec><title>Completion of therapy</title><p>As shown in <xref rid="tbl6" ref-type="table">Table 6</xref>
 <table-wrap id="tbl6" position="float"><label>Table 6</label><caption><p content-type="table-title">Chemotherapy dose intensity</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="5" align="center" valign="top" charoff="50"><bold>Chemotherapy (cycle no.)</bold><hr/></th><th align="left" valign="top" charoff="50">&#x000a0;</th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><bold>No. 1</bold></th><th align="center" valign="top" charoff="50"><bold>No. 2</bold></th><th align="center" valign="top" charoff="50"><bold>No. 3</bold></th><th align="center" valign="top" charoff="50"><bold>No. 4</bold></th><th align="center" valign="top" charoff="50"><bold>All</bold></th><th align="center" valign="top" charoff="50"><bold>Dose intensity<sup>a</sup></bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Cisplatin</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">87&#x000b1;19&#x00025;</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;Real&#x0002f;projected dose (&#x00025;)</td><td align="right" valign="top" charoff="50">101</td><td align="right" valign="top" charoff="50">99</td><td align="right" valign="top" charoff="50">95</td><td align="center" valign="top" charoff="50">89</td><td align="center" valign="top" charoff="50">96</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;No. of patients administered</td><td align="right" valign="top" charoff="50">42</td><td align="right" valign="top" charoff="50">41</td><td align="right" valign="top" charoff="50">40</td><td align="center" valign="top" charoff="50">37</td><td align="center" valign="top" charoff="50">36<sup>b</sup></td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;No. of patients administered with dose reduction</td><td align="right" valign="top" charoff="50">0</td><td align="right" valign="top" charoff="50">0</td><td align="right" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">2</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Docetaxel</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">86&#x000b1;20&#x00025;</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;Real&#x0002f;projected dose (&#x00025;)</td><td align="right" valign="top" charoff="50">101</td><td align="right" valign="top" charoff="50">99</td><td align="right" valign="top" charoff="50">93</td><td align="center" valign="top" charoff="50">87</td><td align="center" valign="top" charoff="50">95</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;No. of patients administered</td><td align="right" valign="top" charoff="50">42</td><td align="right" valign="top" charoff="50">41</td><td align="right" valign="top" charoff="50">40</td><td align="center" valign="top" charoff="50">37</td><td align="center" valign="top" charoff="50">36<sup>b</sup></td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;No. of patients administered with dose reduction</td><td align="right" valign="top" charoff="50">0</td><td align="right" valign="top" charoff="50">0</td><td align="right" valign="top" charoff="50">7</td><td align="center" valign="top" charoff="50">6</td><td align="center" valign="top" charoff="50">7</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;Median interval between Chemotherapy, days (range)</td><td align="right" valign="top" charoff="50">7</td><td align="right" valign="top" charoff="50">21</td><td align="right" valign="top" charoff="50">7</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="right" valign="top" char="(" charoff="50">(7&#x02013;12)</td><td align="right" valign="top" char="(" charoff="50">(21&#x02013;51)</td><td align="right" valign="top" char="(" charoff="50">(7&#x02013;33)</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote8"><label>a</label><p>Indicates administered dose per time unit&#x0002f;projected dose per time unit (mean&#x000b1;s.d.).</p></fn><fn id="tbfnote9"><label>b</label><p>One patient skipped chemotherapy only on day 8.</p></fn></table-wrap-foot></table-wrap>, 36 of 42 (86&#x00025;) patients completed chemotherapy as planned. One patient skipped chemotherapy only on day 8. Doses of cisplatin and docetaxel were reduced in two (5&#x00025;) and seven (17&#x00025;) patients, respectively. Reasons for not completing chemotherapy were toxicity (<italic>n</italic>&#x0003d;3), patient refusal (<italic>n</italic>&#x0003d;1), or physician discretion (<italic>n</italic>&#x0003d;2). The median interval (range) between chemotherapy courses 1 and 2, courses 2 and 3, and courses 3 and 4 were 7 days (7&#x02013;12 days), 21 days (21&#x02013;51 days), and 7 days (7&#x02013;33 days), respectively. Ratios of actual to projected doses of cisplatin and docetaxel were 96 and 95&#x00025;, respectively. As shown in <xref rid="tbl7" ref-type="table">Table 7</xref>
 <table-wrap id="tbl7" position="float"><label>Table 7</label><caption><p content-type="table-title">Schedule of chemotherapy compliance</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="5" align="center" valign="top" char="(" charoff="50"><bold>Days from the beginning of concomitant chemoradiotherapy</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" char="(" charoff="50"><bold>Cycle No. 1 (on day 1)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>No. 2 (on day 8)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>No. 3 (on day 29)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>No. 4 (on day 36)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>No. 3 and&#x0002f;or No. 4 (on day 43 or later)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">No. of patients administered (&#x00025;)</td><td align="center" valign="top" char="(" charoff="50">42 (100)</td><td align="center" valign="top" char="(" charoff="50">41 (98)</td><td align="center" valign="top" char="(" charoff="50">28 (67)</td><td align="center" valign="top" char="(" charoff="50">24 (57)</td><td align="center" valign="top" char="(" charoff="50">13 (31)</td></tr></tbody></table></table-wrap>, 28 (67&#x00025;) and 24 (57&#x00025;) patients were able to receive chemotherapy on time on days 29 and 36, respectively. On day 43 or later, 13 (31&#x00025;) patients received cycles 3 and&#x0002f;or 4 of chemotherapy with or without concurrent radiotherapy. Accordingly, the actual dose intensities of cisplatin and docetaxel were 87 and 86&#x00025;, respectively.</p><p>A total of 36 (86&#x00025;) patients completed radiation therapy (<xref rid="tbl8" ref-type="table">Table 8</xref>
 <table-wrap id="tbl8" position="float"><label>Table 8</label><caption><p content-type="table-title">Compliance with radiotherapy</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Thoracic radiation therapy</bold></th><th align="center" valign="top" charoff="50"><bold>No. (&#x00025;) of patients</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Completed</td><td align="center" valign="top" char="(" charoff="50">36 (86)</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;without rest period</td><td align="center" valign="top" char="(" charoff="50">28 (67)</td></tr><tr><td align="center" valign="top" charoff="50">&#x02003;with rest period</td><td align="center" valign="top" char="(" charoff="50">8 (19)</td></tr><tr><td align="left" valign="top" charoff="50">Not completed</td><td align="center" valign="top" char="(" charoff="50">6 (14)</td></tr></tbody></table></table-wrap>); however, eight (19&#x00025;) required a rest from radiation (median, 10 days; range, 4&#x02013;28 days) due to granulocytopenia (<italic>n</italic>&#x0003d;6), radiation oesophagitis (<italic>n</italic>&#x0003d;1), and granulocytopenia plus oesophagitis (<italic>n</italic>&#x0003d;1). Reasons for not completing radiation therapy were radiation oesophagitis (<italic>n</italic>&#x0003d;3), radiation pneumonitis (<italic>n</italic>&#x0003d;1), patient refusal (<italic>n</italic>&#x0003d;1), or physician discretion (<italic>n</italic>&#x0003d;1). The total mean radiation doses and durations were 57.2&#x02009;Gy and 45.6 days, respectively. Overall, 57&#x00025; of 42 patients completed both chemotherapy and radiation therapy without any modifications according to the protocol.</p><p>Three (7&#x00025;) patients who achieved PR (determined by CT scan) after completing chemoradiotherapy underwent surgery, although this was not part of the study protocol. Postsurgically, two patients with T4N2 disease were downstaged to a pathological CR and pT1N0 disease, and one patient with T2N2 disease still had pT1N2 disease. Microscopic assessment of pT1N0 and pT1N2 tumour samples demonstrated only a few scattered viable tumour cells in necrotic tissue of a primary tumour and&#x0002f;or a mediastinal lymph node. These three patients were still alive without recurrence at the last follow-up evaluation (25, 27, and 36 months, respectively).</p></sec></sec></sec><sec><title>DISCUSSION</title><p>This phase I&#x0002f;II study demonstrated encouraging results with concomitant chemoradiotherapy using cisplatin and docetaxel in patients with advanced NSCLC. In the phase I portion of the study, the maximum tolerated chemotherapy doses were determined to be docetaxel 45&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and cisplatin 40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>. The most common DLTs were radiation oesophagitis and myelosuppression. Recommended doses for the phase II study were docetaxel 40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and cisplatin 40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>. In the phase II portion of the study, 79&#x00025; of patients responded to concomitant chemoradiotherapy with cisplatin and docetaxel, with a median survival time &#x0003e;23 months, and survival rates of 76&#x00025; at 1 year and 54&#x00025; at 2 years.</p><p>One reason for the favourable results may be the dose intensities of cisplatin and docetaxel achieved in this trial. The doses of docetaxel and cisplatin with concurrent standard radiotherapy (60&#x02009;Gy in 6 weeks) were escalated more than we expected in the phase I portion. We did not plan dose levels 6&#x02013;8 at the beginning of this trial, because standard doses without concurrent thoracic radiation therapy in Japan were docetaxel 60&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and cisplatin 80&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> at a 3-week interval (<xref ref-type="other" rid="bib19">Kubota <italic>et al</italic>, 2002</xref>), which corresponded to docetaxel 30&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and cisplatin 40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> on days 1 and 8 at dose level 5. In the phase II portion, the projected dose intensity of both cisplatin and docetaxel in combination with 60&#x02009;Gy standard thoracic radiation therapy was 27&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> week<sup>&#x02212;1</sup>, which was comparable to full doses of docetaxel and cisplatin at a 3-week interval (<xref ref-type="other" rid="bib45">Zalcberg <italic>et al</italic>, 1998</xref>). This study demonstrated that the divided schedule could result in similar dose intensities as a weekly schedule. Thus, chemotherapy doses with concomitant chemoradiotherapy in the current trial were similar to or higher than those in the previous phase II trials that did not include concurrent thoracic radiotherapy.</p><p>Another advantage of the present regimen is the flexibility of the treatment schedule. To reduce toxicity, we often use the divided schedule on days 1 and 8 as previously reported (<xref ref-type="other" rid="bib40">Ueoka <italic>et al</italic>, 1998</xref>, <xref ref-type="other" rid="bib41">1999</xref>, <xref ref-type="other" rid="bib42">2001</xref>; <xref ref-type="other" rid="bib10">Date <italic>et al</italic>, 2002</xref>). We conducted a previous, unsuccessful dose-escalation trial of cisplatin&#x0002f;etoposide chemotherapy in a divided schedule with concurrent thoracic radiation therapy (<xref ref-type="other" rid="bib35">Segawa <italic>et al</italic>, 2003</xref>). In that trial, we strictly fixed the chemotherapy administration on days 29 and 36, and dose and schedule modifications were inhibited on days 29 and 36. Based on that failure, this protocol included the flexible dose and schedule modifications. Accordingly, chemotherapy could be fully administered on days 1 and 8 to all except one patient. On days 29, 36, or later, dosing was individualised according to the prescribed dose and schedule modifications.</p><p>Toxicity, although significant, was tolerable according to the dose and schedule modifications of the protocol. In the phase II portion of the study, 76&#x00025; of 42 patients experienced any grade &#x02a7e;3 toxicity, most commonly grade &#x02a7e;3 granulocytopenia. However, 57&#x00025; of 42 patients completed both chemotherapy and radiation therapy without any modifications, and 88&#x00025; of 42 patients were able to complete the planned chemotherapy and 86&#x00025; completed radiation therapy according to dose and schedule modifications of the protocol. The dose modifications of chemotherapy based on haematogic toxicity were carried out on days 8, 29, and 36. Leukopenia&#x0002f;granulocytopenia is transient and easily controlled by <italic>r</italic>hG-CSF, and life-threatening infections or treatment-related deaths by acute toxicity were not experienced. Grade &#x02a7e;3 radiation oesophagitis occurred in 19&#x00025; of patients, which was comparable to that occurring with other concomitant chemoradiotherapy regimens (e.g., 20&#x00025; with cisplatin and etoposide (<xref ref-type="other" rid="bib1">Albain <italic>et al</italic>, 2002</xref>), 26&#x00025; with cisplatin and paclitaxel (<xref ref-type="other" rid="bib30">Robert <italic>et al</italic>, 2002</xref>), and 46&#x00025; with carboplatin and paclitaxel (<xref ref-type="other" rid="bib5">Choy <italic>et al</italic>, 1998</xref>)). We have observed a low incidence of grade &#x02a7e;3 radiation pneumonitis among patients analysed at a median follow-up time of 26 months in the phase II portion. When paclitaxel&#x0002f;cisplatin was combined with concurrent radiation therapy, 20&#x00025; of grade &#x02a7e;3 late lung toxicity including 8&#x00025; of grade 5 was reported (<xref ref-type="other" rid="bib30">Robert <italic>et al</italic>, 2002</xref>). Mauer also reported two cases (7&#x00025;) of grade 5 pulmonary toxicity using docetaxel with concurrent radiotherapy. In our trial, the incidence of grade &#x02a7e;3 radiation pneumonitis is low. Although careful follow-up for late radiation pneumonitis is needed, there was no additional grade &#x02a7e;3 radiation pneumonitis in April 2003.</p><p>Chemotherapy was postponed or skipped on day 29 in 33&#x00025; of the patients and on day 36 in 43&#x00025; of patients, although the real&#x0002f;projected doses of cisplatin and docetaxel were 96 and 95&#x00025;, respectively. Radiation treatment delays were observed in 19&#x00025; of patients, and 14&#x00025; did not complete radiation therapy. While treatment compliance is very important, a goal of chemoradiotherapy for locally advanced NSCLS is cure. We increased the chemotherapy doses to the limit, even if that slightly decreased compliance to radiotherapy. In this study, dose and schedule modifications worked very well, and there was no acute treatment-related death.</p><p>According to the current phase II trials, concomitant chemoradiotherapy is required to attain median survival time exceeding 17 months, survival rates &#x02a7e;65&#x00025; at 1 year and &#x02a7e;35 &#x00025; at 2 years, and &#x02a7d;50&#x00025; grade 3&#x0002f;4 toxicity in stage III NSCLC (<xref ref-type="other" rid="bib16">Gandara <italic>et al</italic>, 2001</xref>). Survival has to be balanced against toxicity and compliance. The current trial succeeds in achieving satisfactory 1-year and 2-year survival rates, whereas improvements are needed in reducing toxicities and enhancing compliance in the future.</p><p>Recently, the Southwest Oncology Group (SWOG) trial 9504 evaluated docetaxel as consolidation therapy after full-dose cisplatin and etoposide with concurrent radiotherapy (<xref ref-type="other" rid="bib16">Gandara <italic>et al</italic>, 2001</xref>). The updated results were very impressive, with a 26-month median survival time and survival rates of 76&#x00025; at 1 year and 53&#x00025; at 2 years, although patients with pathological stage IIIB disease were enrolled. Direct comparison of the results is very difficult, because our study included eight (19&#x00025;) patients with stage IIIA disease in the phase II portion and excluded minimal pathological N2 or N3 disease by mediastinoscopy. The treatment period of our schedule was shorter by at least 9 weeks compared with that in SWOG 9504. For the patients with stage III disease who receive adjuvant surgery, the shorter treatment period might have an advantage.</p><p>Many clinical trials are now assessing combinations of taxanes, platinums, and concurrent radiotherapy for patients with locally advanced NSCLC. <xref ref-type="other" rid="bib13">Frasci <italic>et al</italic> (1997)</xref> suggested that weekly cisplatin&#x0002f;paclitaxel could be safely administered with concurrent standard radiotherapy. <xref ref-type="other" rid="bib30">Robert <italic>et al</italic> (2002)</xref> reported the feasibility of cisplatin&#x0002f;paclitaxel and conventional radiation therapy. <xref ref-type="other" rid="bib44">Wu <italic>et al</italic> (2002)</xref> reported that the RDs of docetaxel and cisplatin administered weekly with concurrent radiotherapy were both 20&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>. <xref ref-type="other" rid="bib5">Choy <italic>et al</italic> (1998)</xref> reported a phase II study of weekly paclitaxel (50&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) and carboplatin at area under the curve 2 with concurrent radiation therapy.</p><p>It is very difficult to select the ideal drugs for concurrent radiotherapy. We prefer to use cisplatin in a concomitant chemoradiotherapy regimen when we pursue the CR. First, <xref ref-type="other" rid="bib34">Schaake-Koning <italic>et al</italic> (1992)</xref> demonstrated that daily cisplatin acted as a radiosensitiser in a phase III trial as well as in <italic>ex vivo</italic> and <italic>in vivo</italic> experiments. Second, although a Hoosier Oncology Group study reported that cisplatin administered every 3 weeks and concurrent radiotherapy did not improve overall survival, the data indicated possible improved long-term survival with concomitant chemoradiotherapy (<xref ref-type="other" rid="bib4">Blanke <italic>et al</italic>, 1995</xref>). Patients treated with the combination therapy had 3- and 5-year survival rates of 9 and 5&#x00025;, respectively, whereas the rates were 3 and 2&#x00025; with radiation alone. Recent results from a large, international phase III trial comparing docetaxel&#x0002f;cisplatin, docetaxel&#x0002f;carboplatin, and vinorelbine&#x0002f;cisplatin seem to favour the docetaxel&#x0002f;cisplatin combination even in patients with advanced NSCLC (<xref ref-type="other" rid="bib31">Rodriguez <italic>et al</italic>, 2001</xref>). Moreover, paclitaxel&#x0002f;cisplatin has shown significantly longer median survival when compared to paclitaxel&#x0002f;carboplatin (<xref ref-type="other" rid="bib32">Rosell <italic>et al</italic>, 2002</xref>).</p><p>Taxanes are also very attractive drugs for concomitant chemoradiotherapy. Taxanes are known to enhance radiation sensitivity of tumour cells through processes including the following: (1) reoxygenation of hypoxic cells within the tumour, since taxane-killed cells are removed by apoptosis (<xref ref-type="other" rid="bib26">Milas <italic>et al</italic>, 1995</xref>), (2) arrest of cells in both G<sub>2</sub> and M phases, the most radiation-sensitive phases of the cell cycle (<xref ref-type="other" rid="bib38">Tishler <italic>et al</italic>, 1992</xref>), and (3) mobilisation of T cells and natural killer cells to the tumour (<xref ref-type="other" rid="bib23">Mason <italic>et al</italic>, 2001</xref>). Although the majority of studies including taxanes have assessed paclitaxel, radiosensitisation with docetaxel has also been demonstrated both <italic>ex vivo</italic> and <italic>in vivo</italic>. (<xref ref-type="other" rid="bib22">Mason <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib8">Creane <italic>et al</italic>, 1999</xref>) Moreover, docetaxel combined with radiation showed a synergistic or additive effect in NSCLC cell lines tested both <italic>ex vivo</italic> and <italic>in vivo</italic> (<xref ref-type="other" rid="bib27">Nishizaki <italic>et al</italic>, 2001</xref>). In a clinical trial of docetaxel used weekly at the MTD, no grade 4 myelosuppression or peripheral neuropathy was observed (<xref ref-type="other" rid="bib18">Hainsworth <italic>et al</italic>, 1998</xref>). The divided schedule might also prove advantageous when combined with cisplatin and concurrent radiotherapy based on nonoverlapping toxicities like a weekly schedule of docetaxel.</p><p>There is no evidence of the superiority of concomitant chemoradiotherapy using new drugs (taxanes, vinorelbine)&#x0002f;cisplatin as compared with the older standard, full-dose, cisplatin-based chemotherapy. Our group is now conducting a phase III trial of docetaxel&#x0002f;cisplatin <italic>vs</italic> mitomycin&#x0002f;vindesine&#x0002f;cisplatin with concurrent thoracic radiotherapy.</p><p>In conclusion, a regimen comprising cisplatin, docetaxel, and radiation is an exciting approach in the treatment of locally advanced NSCLC. The results of our study showed that chemotherapy consisting of cisplatin and docetaxel given on days 1, 8, 29, and 36 with concurrent radiation therapy might be the effective treatment modality in patients with locally advanced NSCLC.</p></sec></body><back><ack><p>We thank Drs Masaaki Kataoka (National Shikoku Cancer Center Hospital), Noriko Kanzaki (National South Okayama Hospital), Hidehiro Hayashi (Okayama Red Cross Hospital), and Katsuyoshi Sakae (National Sanyo Hospital) for their collaborations as radiation oncologists.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Albain</surname><given-names>KS</given-names></name><name><surname>Crowley</surname><given-names>JJ</given-names></name><name><surname>Turrisi</surname><given-names>AT</given-names><suffix>III</suffix></name><name><surname>Gandara</surname><given-names>DR</given-names></name><name><surname>Farrar</surname><given-names>WB</given-names></name><name><surname>Clark</surname><given-names>JI</given-names></name><name><surname>Beasley</surname><given-names>KR</given-names></name><name><surname>Robert</surname><given-names>B</given-names></name><name><surname>Livingston</surname><given-names>RB</given-names></name></person-group><article-title>Concurrent cisplatin, etoposide, and chest radiotherapy in pathological stage IIIB non-small-cell lung cancer: a Southwest Oncology Group Phase II study, SWOG 9019</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>3454</fpage><lpage>3460</lpage><!--PubMed citation query: 'J Clin Oncol||20|3454||bib1|'--><pub-id pub-id-type="pmid">12177106</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname><given-names>MV</given-names></name><name><surname>Cobreros</surname><given-names>G</given-names></name><name><surname>Heras</surname><given-names>A</given-names></name><name><surname>Lopez Zumel</surname><given-names>MC</given-names></name></person-group><article-title>Studies on cis-dichloro diammineplatinum (II) as a radiosensitizer</article-title><source>Br J Cancer</source><year>1978</year><volume>37</volume><supplement>Suppl</supplement><fpage>S68</fpage><lpage>S72</lpage><!--PubMed citation query: 'Br J Cancer||37|S68||bib2|'--></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aoe</surname><given-names>K</given-names></name><name><surname>Kiura</surname><given-names>K</given-names></name><name><surname>Ueoka</surname><given-names>H</given-names></name><name><surname>Tabata</surname><given-names>M</given-names></name><name><surname>Matsumura</surname><given-names>T</given-names></name><name><surname>Chikamori</surname><given-names>M</given-names></name><name><surname>Matsushita</surname><given-names>A</given-names></name><name><surname>Kohara</surname><given-names>H</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name></person-group><article-title>Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines</article-title><source>Anticancer Res</source><year>1999</year><volume>19</volume><supplement>1A</supplement><fpage>291</fpage><lpage>299</lpage><!--PubMed citation query: 'Anticancer Res||19|291||bib3|'--><pub-id pub-id-type="pmid">10226557</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blanke</surname><given-names>C</given-names></name><name><surname>Ansari</surname><given-names>R</given-names></name><name><surname>Mantravadi</surname><given-names>R</given-names></name><name><surname>Gonin</surname><given-names>R</given-names></name><name><surname>Tokars</surname><given-names>R</given-names></name><name><surname>Fisher</surname><given-names>W</given-names></name><name><surname>Pennington</surname><given-names>K</given-names></name><name><surname>O'Connor</surname><given-names>T</given-names></name><name><surname>Rynard</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Einhorn</surname><given-names>L</given-names></name></person-group><article-title>Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol</article-title><source>J Clin Oncol</source><year>1995</year><volume>13</volume><fpage>1425</fpage><lpage>1429</lpage><!--PubMed citation query: 'J Clin Oncol||13|1425||bib4|'--><pub-id pub-id-type="pmid">7751888</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Choy</surname><given-names>H</given-names></name><name><surname>Akerley</surname><given-names>W</given-names></name><name><surname>Safran</surname><given-names>H</given-names></name><name><surname>Graziano</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>T</given-names></name><name><surname>Cole</surname><given-names>B</given-names></name><name><surname>Kennedy</surname><given-names>T</given-names></name></person-group><article-title>Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>3316</fpage><lpage>3322</lpage><!--PubMed citation query: 'J Clin Oncol||16|3316||bib5|'--><pub-id pub-id-type="pmid">9779707</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>JD</given-names></name><name><surname>Stetz</surname><given-names>J</given-names></name><name><surname>Pajak</surname><given-names>TF</given-names></name></person-group><article-title>Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1995</year><volume>31</volume><fpage>1341</fpage><lpage>1346</lpage><!--PubMed citation query: 'Int J Radiat Oncol Biol Phys||31|1341||bib7|'--><pub-id pub-id-type="pmid">7713792</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Creane</surname><given-names>M</given-names></name><name><surname>Seymour</surname><given-names>CB</given-names></name><name><surname>Colucci</surname><given-names>S</given-names></name><name><surname>Mothersill</surname><given-names>C</given-names></name></person-group><article-title>Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizer</article-title><source>Int J Radiat Biol</source><year>1999</year><volume>75</volume><fpage>731</fpage><lpage>737</lpage><!--PubMed citation query: 'Int J Radiat Biol||75|731||bib8|'--><pub-id pub-id-type="pmid">10405003</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Curran</surname><given-names>WJ</given-names></name><name><surname>Scott</surname><given-names>C</given-names></name><name><surname>Langer</surname><given-names>C</given-names></name><name><surname>Komaki</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Hauser</surname><given-names>S</given-names></name><name><surname>Movsas</surname><given-names>B</given-names></name><name><surname>Wasserman</surname><given-names>T</given-names></name><name><surname>Rosenthal</surname><given-names>S</given-names></name><name><surname>Byhardt</surname><given-names>R</given-names></name><name><surname>Sause</surname><given-names>W</given-names></name><name><surname>Cox</surname><given-names>J</given-names></name></person-group><article-title>Phase III comparison of sequential <italic>vs</italic> concurrent chemoradiation for patients (pts) with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410</article-title><source>Proc Am Soc Clin Oncol</source><year>2000</year><volume>19</volume><fpage>484</fpage>Abstr<!--PubMed citation query: 'Proc Am Soc Clin Oncol||19|484||bib9|'--></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Date</surname><given-names>H</given-names></name><name><surname>Kiura</surname><given-names>K</given-names></name><name><surname>Ueoka</surname><given-names>H</given-names></name><name><surname>Tabata</surname><given-names>M</given-names></name><name><surname>Aoe</surname><given-names>M</given-names></name><name><surname>Andou</surname><given-names>A</given-names></name><name><surname>Shibayama</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name></person-group><article-title>Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer</article-title><source>Br J Cancer</source><year>2002</year><volume>86</volume><fpage>530</fpage><lpage>533</lpage><!--PubMed citation query: 'Br J Cancer||86|530||bib10|'--><pub-id pub-id-type="pmid">11870532</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dewit</surname><given-names>L</given-names></name></person-group><article-title>Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1987</year><volume>13</volume><fpage>403</fpage><lpage>426</lpage><!--PubMed citation query: 'Int J Radiat Oncol Biol Phys||13|403||bib11|'--><pub-id pub-id-type="pmid">3549645</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dillman</surname><given-names>RO</given-names></name><name><surname>Herndon</surname><given-names>J</given-names></name><name><surname>Seagren</surname><given-names>SL</given-names></name><name><surname>Eaton</surname><given-names>WL</given-names><suffix>Jr</suffix></name><name><surname>Green</surname><given-names>MR</given-names></name></person-group><article-title>Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial</article-title><source>J Natl Cancer Inst</source><year>1996</year><volume>88</volume><fpage>1210</fpage><lpage>1215</lpage><!--PubMed citation query: 'J Natl Cancer Inst||88|1210||bib12|'--><pub-id pub-id-type="pmid">8780630</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frasci</surname><given-names>G</given-names></name><name><surname>Comella</surname><given-names>P</given-names></name><name><surname>Scoppa</surname><given-names>G</given-names></name><name><surname>Guida</surname><given-names>C</given-names></name><name><surname>Gravina</surname><given-names>A</given-names></name><name><surname>Fiore</surname><given-names>F</given-names></name><name><surname>Casaretti</surname><given-names>R</given-names></name><name><surname>Daponte</surname><given-names>A</given-names></name><name><surname>Parziale</surname><given-names>A</given-names></name><name><surname>Comella</surname><given-names>G</given-names></name></person-group><article-title>Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>1409</fpage><lpage>1417</lpage><!--PubMed citation query: 'J Clin Oncol||15|1409||bib13|'--><pub-id pub-id-type="pmid">9193333</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furuse</surname><given-names>K</given-names></name><name><surname>Fukuoka</surname><given-names>M</given-names></name><name><surname>Kawahara</surname><given-names>M</given-names></name><name><surname>Nishikawa</surname><given-names>H</given-names></name><name><surname>Takada</surname><given-names>Y</given-names></name><name><surname>Kudoh</surname><given-names>S</given-names></name><name><surname>Katagami</surname><given-names>N</given-names></name><name><surname>Ariyoshi</surname><given-names>Y</given-names></name></person-group><article-title>Phase III study of concurrent <italic>versus</italic> sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>2692</fpage><lpage>2699</lpage><!--PubMed citation query: 'J Clin Oncol||17|2692||bib14|'--><pub-id pub-id-type="pmid">10561343</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giaccone</surname><given-names>G</given-names></name><name><surname>Manegold</surname><given-names>C</given-names></name><name><surname>Rosell</surname><given-names>R</given-names></name><name><surname>Gatzemeier</surname><given-names>U</given-names></name><name><surname>Quoix</surname><given-names>E</given-names></name></person-group><article-title>An update on European randomized studies in non-small cell lung cancer</article-title><source>Semin Oncol</source><year>1998</year><volume>25</volume><supplement>4 Suppl 9</supplement><fpage>11</fpage><lpage>17</lpage><!--PubMed citation query: 'Semin Oncol||25|11||bib15|'--></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gandara</surname><given-names>DR</given-names></name><name><surname>Lara</surname><given-names>PN</given-names><suffix>Jr</suffix></name><name><surname>Goldberg</surname><given-names>Z</given-names></name><name><surname>Lau</surname><given-names>DH</given-names></name></person-group><article-title>Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non-small cell lung cancer: focus on docetaxel</article-title><source>Semin Oncol</source><year>2001</year><volume>28</volume><supplement>Suppl 9</supplement><fpage>S26</fpage><lpage>S32</lpage><!--PubMed citation query: 'Semin Oncol||28|S26||bib16|'--></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greco</surname><given-names>FA</given-names></name><name><surname>Stroup</surname><given-names>SL</given-names></name><name><surname>Gray</surname><given-names>JR</given-names></name><name><surname>Hainsworth</surname><given-names>JD</given-names></name></person-group><article-title>Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>1996</year><volume>14</volume><fpage>1642</fpage><lpage>1648</lpage><!--PubMed citation query: 'J Clin Oncol||14|1642||bib17|'--><pub-id pub-id-type="pmid">8622083</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hainsworth</surname><given-names>JD</given-names></name><name><surname>Burris</surname><given-names>HA</given-names></name><name><surname>Erland</surname><given-names>JB</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Greco</surname><given-names>FA</given-names></name></person-group><article-title>Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>2164</fpage><lpage>2168</lpage><!--PubMed citation query: 'J Clin Oncol||16|2164||bib18|'--><pub-id pub-id-type="pmid">9626217</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kubota</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Kunitoh</surname><given-names>H</given-names></name><name><surname>Noda</surname><given-names>K</given-names></name><name><surname>Ichinose</surname><given-names>Y</given-names></name><name><surname>Katakami</surname><given-names>N</given-names></name><name><surname>Sugiura</surname><given-names>T</given-names></name><name><surname>Kawahara</surname><given-names>M</given-names></name><name><surname>Yokoyama</surname><given-names>A</given-names></name><name><surname>Nishiwaki</surname><given-names>Y</given-names></name><name><surname>Ohashi</surname><given-names>A</given-names></name><name><surname>Niitani</surname><given-names>H</given-names></name></person-group><article-title>Final results of a randomized phase III trial of docetaxel and cisplatin <italic>versus</italic> vindesine and cisplatin in stage IV non-small cell lung cancer (NSCLC)</article-title><source>Proc Am Soc Clin Oncol</source><year>2002</year><volume>21</volume><fpage>296a</fpage>(Abstr 1180)<!--PubMed citation query: 'Proc Am Soc Clin Oncol||21|296a||bib19|'--></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Scott</surname><given-names>C</given-names></name><name><surname>Komaki</surname><given-names>R</given-names></name><name><surname>Fossella</surname><given-names>FV</given-names></name><name><surname>Dundas</surname><given-names>GS</given-names></name><name><surname>McDonald</surname><given-names>S</given-names></name><name><surname>Byhardt</surname><given-names>RW</given-names></name><name><surname>Curran</surname><given-names>WJ</given-names><suffix>Jr</suffix></name></person-group><article-title>Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06</article-title><source>J Clin Oncol</source><year>1996</year><volume>14</volume><supplement>4</supplement><fpage>1055</fpage><lpage>1064</lpage><!--PubMed citation query: 'J Clin Oncol||14|1055||bib20|'--><pub-id pub-id-type="pmid">8648357</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marino</surname><given-names>P</given-names></name><name><surname>Preatoni</surname><given-names>A</given-names></name><name><surname>Cantoni</surname><given-names>A</given-names></name></person-group><article-title>Randomized trials of radiotherapy alone <italic>versus</italic> combined chemotherapy and radiotherapy in stages IIIa and IIIb non small cell lung cancer. A meta analysis</article-title><source>Cancer</source><year>1995</year><volume>76</volume><fpage>593</fpage><lpage>601</lpage><!--PubMed citation query: 'Cancer||76|593||bib21|'--><pub-id pub-id-type="pmid">8625152</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>KA</given-names></name><name><surname>Hunter</surname><given-names>NR</given-names></name><name><surname>Milas</surname><given-names>M</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name><name><surname>Milas</surname><given-names>L</given-names></name></person-group><article-title>Docetaxel enhances tumor radioresponse <italic>in vivo</italic></article-title><source>Clin Cancer Res</source><year>1997</year><volume>3</volume><fpage>2431</fpage><lpage>2438</lpage><!--PubMed citation query: 'Clin Cancer Res||3|2431||bib22|'--><pub-id pub-id-type="pmid">9815644</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>K</given-names></name><name><surname>Staab</surname><given-names>A</given-names></name><name><surname>Hunter</surname><given-names>N</given-names></name><name><surname>McBride</surname><given-names>W</given-names></name><name><surname>Petersen</surname><given-names>S</given-names></name><name><surname>Terry</surname><given-names>N</given-names></name><name><surname>Milas</surname><given-names>L</given-names></name></person-group><article-title>Enhancement of tumor radioresponse by docetaxel: involvement of immune system</article-title><source>Int J Oncol</source><year>2001</year><volume>18</volume><fpage>599</fpage><lpage>606</lpage><!--PubMed citation query: 'Int J Oncol||18|599||bib23|'--><pub-id pub-id-type="pmid">11179493</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsushita</surname><given-names>A</given-names></name><name><surname>Tabata</surname><given-names>M</given-names></name><name><surname>Ueoka</surname><given-names>H</given-names></name><name><surname>Kiura</surname><given-names>K</given-names></name><name><surname>Shibayama</surname><given-names>T</given-names></name><name><surname>Aoe</surname><given-names>K</given-names></name><name><surname>Kohara</surname><given-names>H</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name></person-group><article-title>Establishment of a drug sensitivity panel using human lung cancer cell lines</article-title><source>Acta Med Okayama</source><year>1999</year><volume>53</volume><fpage>67</fpage><lpage>75</lpage><!--PubMed citation query: 'Acta Med Okayama||53|67||bib24|'--><pub-id pub-id-type="pmid">10358721</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mauer</surname><given-names>AM</given-names></name><name><surname>Masters</surname><given-names>GA</given-names></name><name><surname>Haraf</surname><given-names>DJ</given-names></name><name><surname>Hoffman</surname><given-names>PC</given-names></name><name><surname>Watson</surname><given-names>SM</given-names></name><name><surname>Golomb</surname><given-names>HM</given-names></name><name><surname>Vokes</surname><given-names>EE</given-names></name></person-group><article-title>Phase I study of docetaxel with concomitant thoracic radiation therapy</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>159</fpage><lpage>164</lpage><!--PubMed citation query: 'J Clin Oncol||16|159||bib25|'--><pub-id pub-id-type="pmid">9440738</pub-id></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milas</surname><given-names>L</given-names></name><name><surname>Hunter</surname><given-names>NR</given-names></name><name><surname>Mason</surname><given-names>KA</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name></person-group><article-title>Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><fpage>3564</fpage><lpage>3568</lpage><!--PubMed citation query: 'Cancer Res||55|3564||bib26|'--><pub-id pub-id-type="pmid">7627965</pub-id></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nishizaki</surname><given-names>M</given-names></name><name><surname>Meyn</surname><given-names>RE</given-names></name><name><surname>Levy</surname><given-names>LB</given-names></name><name><surname>Atkinson</surname><given-names>EN</given-names></name><name><surname>White</surname><given-names>RA</given-names></name><name><surname>Roth</surname><given-names>JA</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name></person-group><article-title>Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>Clin Cancer Res</source><year>2001</year><volume>7</volume><fpage>2887</fpage><lpage>2897</lpage><!--PubMed citation query: 'Clin Cancer Res||7|2887||bib27|'--><pub-id pub-id-type="pmid">11555607</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oken</surname><given-names>MM</given-names></name><name><surname>Creech</surname><given-names>RH</given-names></name><name><surname>Tormey</surname><given-names>DC</given-names></name><name><surname>Horton</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>TE</given-names></name><name><surname>McFadden</surname><given-names>ET</given-names></name><name><surname>Carbone</surname><given-names>PP</given-names></name></person-group><article-title>Toxicity and response criteria of the Eastern Cooperative Oncology Group</article-title><source>Am J Clin Oncol</source><year>1982</year><volume>5</volume><fpage>649</fpage><lpage>655</lpage><!--PubMed citation query: 'Am J Clin Oncol||5|649||bib28|'--><pub-id pub-id-type="pmid">7165009</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reboul</surname><given-names>F</given-names></name><name><surname>Brewer</surname><given-names>Y</given-names></name><name><surname>Vincent</surname><given-names>P</given-names></name><name><surname>Chauvet</surname><given-names>B</given-names></name><name><surname>Faure</surname><given-names>CF</given-names></name><name><surname>Taulelle</surname><given-names>M</given-names></name></person-group><article-title>Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1996</year><volume>35</volume><supplement>2</supplement><fpage>343</fpage><lpage>350</lpage><!--PubMed citation query: 'Int J Radiat Oncol Biol Phys||35|343||bib29|'--><pub-id pub-id-type="pmid">8635942</pub-id></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>F</given-names></name><name><surname>Spencer</surname><given-names>SA</given-names></name><name><surname>Childs</surname><given-names>HA</given-names><suffix>III</suffix></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Meredith</surname><given-names>RF</given-names></name><name><surname>Wheeler</surname><given-names>RH</given-names></name><name><surname>Hawkins</surname><given-names>MH</given-names></name><name><surname>Carey</surname><given-names>D</given-names></name></person-group><article-title>Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial</article-title><source>Lung Cancer</source><year>2002</year><volume>37</volume><supplement>2</supplement><fpage>189</fpage><lpage>199</lpage><!--PubMed citation query: 'Lung Cancer||37|189||bib30|'--><pub-id pub-id-type="pmid">12140142</pub-id></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>J</given-names></name><name><surname>Pawel</surname><given-names>J</given-names></name><name><surname>Pluzanska</surname><given-names>A</given-names></name><name><surname>Gorbounova</surname><given-names>V</given-names></name><name><surname>Fossella</surname><given-names>F</given-names></name><name><surname>Kaukel</surname><given-names>E</given-names></name><name><surname>Mattson</surname><given-names>K</given-names></name><name><surname>Millward</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Gamza</surname><given-names>F</given-names></name><name><surname>Berille</surname><given-names>J</given-names></name><name><surname>Belani</surname><given-names>CP</given-names></name></person-group><article-title>Multicenter, randomized phase III study of docetaxel&#x0002b;cisplatin (DC) and docetaxel&#x0002b;carboplatin (DCB) <italic>vs</italic>. vinorelbine&#x0002b;cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer</article-title><source>Proc Am Soc Clin Oncol</source><year>2001</year><volume>20</volume><fpage>314a</fpage>(Abstr 1252)<!--PubMed citation query: 'Proc Am Soc Clin Oncol||20|314a||bib31|'--></citation></ref><ref id="bib32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosell</surname><given-names>R</given-names></name><name><surname>Gatzemeier</surname><given-names>U</given-names></name><name><surname>Betticher</surname><given-names>DC</given-names></name><name><surname>Keppler</surname><given-names>U</given-names></name><name><surname>Macha</surname><given-names>HN</given-names></name><name><surname>Pirker</surname><given-names>R</given-names></name><name><surname>Berthet</surname><given-names>P</given-names></name><name><surname>Breau</surname><given-names>JL</given-names></name><name><surname>Lianes</surname><given-names>P</given-names></name><name><surname>Nicholson</surname><given-names>M</given-names></name><name><surname>Ardizzoni</surname><given-names>A</given-names></name><name><surname>Chemaissani</surname><given-names>A</given-names></name><name><surname>Bogaerts</surname><given-names>J</given-names></name><name><surname>Gallant</surname><given-names>G</given-names></name></person-group><article-title>Phase III randomised trial comparing paclitaxel&#x0002f;carboplatin with paclitaxel&#x0002f;cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial</article-title><source>Ann Oncol</source><year>2002</year><volume>13</volume><fpage>1539</fpage><lpage>1549</lpage><!--PubMed citation query: 'Ann Oncol||13|1539||bib32|'--><pub-id pub-id-type="pmid">12377641</pub-id></citation></ref><ref id="bib33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sause</surname><given-names>W</given-names></name><name><surname>Kolesar</surname><given-names>P</given-names></name><name><surname>Taylor</surname><given-names>S</given-names><suffix>IV</suffix></name><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Livingston</surname><given-names>R</given-names></name><name><surname>Komaki</surname><given-names>R</given-names></name><name><surname>Emami</surname><given-names>B</given-names></name><name><surname>Curran</surname><given-names>W</given-names><suffix>Jr</suffix></name><name><surname>Byhardt</surname><given-names>R</given-names></name><name><surname>Dar</surname><given-names>AR</given-names></name><name><surname>Turrisi</surname><given-names>A</given-names><suffix>III</suffix></name></person-group><article-title>Final results of phase III trial in regionally advanced unresectable nonsmall cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group</article-title><source>Chest</source><year>2000</year><volume>117</volume><fpage>358</fpage><lpage>364</lpage><!--PubMed citation query: 'Chest||117|358||bib33|'--><pub-id pub-id-type="pmid">10669675</pub-id></citation></ref><ref id="bib34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schaake-Koning</surname><given-names>C</given-names></name><name><surname>van den Bogaert</surname><given-names>W</given-names></name><name><surname>Dalesio</surname><given-names>O</given-names></name><name><surname>Festen</surname><given-names>J</given-names></name><name><surname>Hoogenhout</surname><given-names>J</given-names></name><name><surname>van Houtte</surname><given-names>P</given-names></name><name><surname>Kirkpatrick</surname><given-names>A</given-names></name><name><surname>Koolen</surname><given-names>M</given-names></name><name><surname>Maat</surname><given-names>B</given-names></name><name><surname>Nijs</surname><given-names>A</given-names></name></person-group><article-title>Effects of concomitant cisplatin and radiotherapy on Inoperable non-small-cell lung cancer</article-title><source>N Engl J Med</source><year>1992</year><volume>326</volume><fpage>524</fpage><lpage>530</lpage><!--PubMed citation query: 'N Engl J Med||326|524||bib34|'--><pub-id pub-id-type="pmid">1310160</pub-id></citation></ref><ref id="bib35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Segawa</surname><given-names>Y</given-names></name><name><surname>Ueoka</surname><given-names>H</given-names></name><name><surname>Kiura</surname><given-names>K</given-names></name><name><surname>Tabata</surname><given-names>M</given-names></name><name><surname>Takigawa</surname><given-names>N</given-names></name><name><surname>Hiraki</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Yonci</surname><given-names>T</given-names></name><name><surname>Moritaka</surname><given-names>T</given-names></name><name><surname>Hiyama</surname><given-names>J</given-names></name><name><surname>Hiraki</surname><given-names>S</given-names></name><name><surname>Tanimoto</surname><given-names>M</given-names></name><name><surname>Hatada</surname><given-names>M</given-names></name></person-group><article-title>Phase I&#x0002f;II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer</article-title><source>Lung Cancer</source><year>2003</year><volume>41</volume><supplement>1</supplement><fpage>13</fpage><lpage>20</lpage><!--PubMed citation query: 'Lung Cancer||41|13||bib35|'--><pub-id pub-id-type="pmid">12826307</pub-id></citation></ref><ref id="bib36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Segawa</surname><given-names>Y</given-names></name><name><surname>Ueoka</surname><given-names>H</given-names></name><name><surname>Kiura</surname><given-names>K</given-names></name><name><surname>Kamei</surname><given-names>H</given-names></name><name><surname>Tabata</surname><given-names>M</given-names></name><name><surname>Sakae</surname><given-names>K</given-names></name><name><surname>Hiraki</surname><given-names>Y</given-names></name><name><surname>Kawahara</surname><given-names>S</given-names></name><name><surname>Eguchi</surname><given-names>K</given-names></name><name><surname>Hiraki</surname><given-names>S</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name></person-group><article-title>A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group</article-title><source>Br J Cancer</source><year>2000</year><volume>82</volume><supplement>1</supplement><fpage>104</fpage><lpage>111</lpage><!--PubMed citation query: 'Br J Cancer||82|104||bib36|'--><pub-id pub-id-type="pmid">10638975</pub-id></citation></ref><ref id="bib37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>FA</given-names></name><name><surname>Dancey</surname><given-names>J</given-names></name><name><surname>Ramlau</surname><given-names>R</given-names></name><name><surname>Mattson</surname><given-names>K</given-names></name><name><surname>Gralla</surname><given-names>R</given-names></name><name><surname>O'Rourke</surname><given-names>M</given-names></name><name><surname>Levitan</surname><given-names>N</given-names></name><name><surname>Gressot</surname><given-names>L</given-names></name><name><surname>Vincent</surname><given-names>M</given-names></name><name><surname>Burkes</surname><given-names>R</given-names></name><name><surname>Coughlin</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Berille</surname><given-names>J</given-names></name></person-group><article-title>Prospective randomized trial of docetaxel <italic>versus</italic> best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>2095</fpage><lpage>2103</lpage><!--PubMed citation query: 'J Clin Oncol||18|2095||bib37|'--><pub-id pub-id-type="pmid">10811675</pub-id></citation></ref><ref id="bib38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tishler</surname><given-names>RB</given-names></name><name><surname>Geard</surname><given-names>CR</given-names></name><name><surname>Hall</surname><given-names>EJ</given-names></name><name><surname>Schiff</surname><given-names>PB</given-names></name></person-group><article-title>Taxol sensitizes human astrocytoma cells to radiation</article-title><source>Cancer Res</source><year>1992</year><volume>52</volume><fpage>3495</fpage><lpage>3497</lpage><!--PubMed citation query: 'Cancer Res||52|3495||bib38|'--><pub-id pub-id-type="pmid">1350755</pub-id></citation></ref><ref id="bib39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomiak</surname><given-names>E</given-names></name><name><surname>Piccart</surname><given-names>MJ</given-names></name><name><surname>Kerger</surname><given-names>J</given-names></name><name><surname>Lips</surname><given-names>S</given-names></name><name><surname>Awada</surname><given-names>A</given-names></name><name><surname>de Valeriola</surname><given-names>D</given-names></name><name><surname>Ravoet</surname><given-names>C</given-names></name><name><surname>Lossignol</surname><given-names>D</given-names></name><name><surname>Sculier</surname><given-names>JP</given-names></name><name><surname>Auzannet</surname><given-names>V</given-names></name><name><surname>Le Bail</surname><given-names>N</given-names></name><name><surname>Bayssas</surname><given-names>M</given-names></name><name><surname>Klastersky</surname></name></person-group><article-title>Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis</article-title><source>J Clin Oncol</source><year>1994</year><volume>12</volume><fpage>1458</fpage><lpage>1467</lpage><!--PubMed citation query: 'J Clin Oncol||12|1458||bib39|'--><pub-id pub-id-type="pmid">7912725</pub-id></citation></ref><ref id="bib40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueoka</surname><given-names>H</given-names></name><name><surname>Kiura</surname><given-names>K</given-names></name><name><surname>Tabata</surname><given-names>M</given-names></name><name><surname>Kamei</surname><given-names>H</given-names></name><name><surname>Gemba</surname><given-names>K</given-names></name><name><surname>Sakae</surname><given-names>K</given-names></name><name><surname>Hiraki</surname><given-names>Y</given-names></name><name><surname>Hiraki</surname><given-names>S</given-names></name><name><surname>Segawa</surname><given-names>Y</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name></person-group><article-title>A randomized trial of hybrid administration of cyclophosphamide-adriamycin-vincristine (CAV)&#x0002f;cisplatin-etoposide <italic>versus</italic> sequential administration of CAV-PVP for the treatment of small-cell lung cancer: results of long term follow-up</article-title><source>Cancer</source><year>1998</year><volume>83</volume><fpage>283</fpage><lpage>290</lpage><!--PubMed citation query: 'Cancer||83|283||bib40|'--><pub-id pub-id-type="pmid">9669811</pub-id></citation></ref><ref id="bib41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueoka</surname><given-names>H</given-names></name><name><surname>Tabata</surname><given-names>M</given-names></name><name><surname>Kiura</surname><given-names>K</given-names></name><name><surname>Shibayama</surname><given-names>T</given-names></name><name><surname>Gemba</surname><given-names>K</given-names></name><name><surname>Segawa</surname><given-names>Y</given-names></name><name><surname>Chikamori</surname><given-names>K</given-names></name><name><surname>Yonei</surname><given-names>T</given-names></name><name><surname>Hiraki</surname><given-names>S</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name></person-group><article-title>Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study</article-title><source>Br J Cancer</source><year>1999</year><volume>79</volume><supplement>5&#x0002f;6</supplement><fpage>984</fpage><lpage>990</lpage><!--PubMed citation query: 'Br J Cancer||79|984||bib41|'--><pub-id pub-id-type="pmid">10070901</pub-id></citation></ref><ref id="bib42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueoka</surname><given-names>H</given-names></name><name><surname>Tanimoto</surname><given-names>M</given-names></name><name><surname>Kiura</surname><given-names>K</given-names></name><name><surname>Tabata</surname><given-names>M</given-names></name><name><surname>Takigawa</surname><given-names>N</given-names></name><name><surname>Segawa</surname><given-names>Y</given-names></name><name><surname>Takata</surname><given-names>I</given-names></name><name><surname>Eguchi</surname><given-names>K</given-names></name><name><surname>Okimoto</surname><given-names>N</given-names></name><name><surname>Harita</surname><given-names>S</given-names></name><name><surname>Kamei</surname><given-names>H</given-names></name><name><surname>Shibayama</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Hiraki</surname><given-names>S</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name></person-group><article-title>Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group</article-title><source>Br J Cancer</source><year>2001</year><volume>85</volume><supplement>1</supplement><fpage>9</fpage><lpage>13</lpage><!--PubMed citation query: 'Br J Cancer||85|9||bib42|'--><pub-id pub-id-type="pmid">11437395</pub-id></citation></ref><ref id="bib43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Meerbeeck</surname><given-names>JP</given-names></name></person-group><article-title>Staging of non-small cell lung cancer: consensus, controversies and challenges</article-title><source>Lung Cancer</source><year>2001</year><volume>34</volume><supplement>Suppl 2</supplement><fpage>S95</fpage><lpage>S107</lpage><!--PubMed citation query: 'Lung Cancer||34|S95||bib43|'--></citation></ref><ref id="bib44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>HG</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Choi</surname><given-names>EK</given-names></name><name><surname>Ahn</surname><given-names>YC</given-names></name><name><surname>Kim</surname><given-names>YW</given-names></name><name><surname>Lim</surname><given-names>TH</given-names></name><name><surname>Suh</surname><given-names>C</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>CI</given-names></name></person-group><article-title>Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small-cell lung cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2002</year><volume>52</volume><fpage>75</fpage><lpage>80</lpage><!--PubMed citation query: 'Int J Radiat Oncol Biol Phys||52|75||bib44|'--><pub-id pub-id-type="pmid">11777624</pub-id></citation></ref><ref id="bib45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zalcberg</surname><given-names>J</given-names></name><name><surname>Millward</surname><given-names>M</given-names></name><name><surname>Bishop</surname><given-names>J</given-names></name><name><surname>McKeage</surname><given-names>M</given-names></name><name><surname>Zimet</surname><given-names>A</given-names></name><name><surname>Toner</surname><given-names>G</given-names></name><name><surname>Friedlander</surname><given-names>M</given-names></name><name><surname>Barter</surname><given-names>C</given-names></name><name><surname>Rischin</surname><given-names>D</given-names></name><name><surname>Loret</surname><given-names>C</given-names></name><name><surname>James</surname><given-names>R</given-names></name><name><surname>Bougan</surname><given-names>N</given-names></name><name><surname>Berille</surname><given-names>J</given-names></name></person-group><article-title>Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>1948</fpage><lpage>1953</lpage><!--PubMed citation query: 'J Clin Oncol||16|1948||bib45|'--><pub-id pub-id-type="pmid">9586914</pub-id></citation></ref></ref-list></back></article>


